Eosinophilic Asthma Drug Pipeline Analysis Report 2025

Eosinophilic asthma is a subtype of asthma characterized by high levels of eosinophils, a type of white blood cell that causes airway inflammation. It accounts for approximately 50% of all severe asthma cases. There is a significant clinical need for advanced therapies as current treatment options, such as corticosteroids, may be ineffective for some patients. The growing focus on targeted biologics, including interleukin inhibitors like mepolizumab and benralizumab, is expected to drive market growth in the coming years. Advancements in eosinophilic asthma therapeutics aim to improve patient outcomes and address the limitations of existing treatments.

Report Coverage

The Eosinophilic Asthma Drug Pipeline Insight Report by the publisher gives comprehensive insights into eosinophilic asthma therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for eosinophilic asthma. The eosinophilic asthma report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The eosinophilic asthma pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with eosinophilic asthma treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to eosinophilic asthma.

Eosinophilic Asthma Drug Pipeline Outlook

Eosinophilic asthma is a severe form of asthma characterized by elevated eosinophil levels - a type of white blood cell - in the lungs. It occurs due to an overactive immune response, leading to airway inflammation and breathing difficulties. This subtype often develops in adulthood and is not typically triggered by allergens, unlike other asthma types.

Eosinophilic asthma treatments focus on reducing inflammation and managing symptoms. Biologic therapies, such as monoclonal antibodies, target eosinophils directly. Corticosteroids, both inhaled and oral, help control inflammation. Personalized treatment plans are essential, often involving regular monitoring and adjustments to maintain symptom control and prevent exacerbations.

Eosinophilic Asthma Epidemiology

Eosinophilic asthma accounts for about 50% of severe asthma cases. Eosinophilia, or high eosinophil levels, affects 19.6 percent of asthma patients worldwide. In the United States, the prevalence is 18.5 percent, while it is 16 percent in the United Kingdom and 20.7 percent in Spain. In India, eosinophilia is observed in 58% of bronchial asthma patients.

Eosinophilic Asthma - Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of eosinophilic asthma drug candidates based on several segmentations, including:

By Phase

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Drug Class

• Monoclonal Antibodies
• Small Molecules
• Immunomodulators
• Oligonucleotides
• Peptides
• Others

By Route of Administration

• Oral
• Parenteral
• Others

Eosinophilic Asthma - Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase III covers a major share of the total eosinophilic asthma clinical trials.

Eosinophilic Asthma - Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the eosinophilic asthma pipeline analysis include monoclonal antibodies, small molecules, immunomodulators, oligonucleotides, peptides, and others. The eosinophilic asthma report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for eosinophilic asthma.

Eosinophilic Asthma Clinical Trials Therapeutic Assessment - Competitive Dynamics

The report for the eosinophilic asthma drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed eosinophilic asthma therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in eosinophilic asthma clinical trials:

• AstraZeneca
• Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
• Areteia Therapeutics
• Advagene Biopharma Co. Ltd.
• Jiangsu Hengrui Pharmaceuticals. Co., Ltd.
• GlaxoSmithKline
• Parexel
• Advagene Biopharma Co. Ltd.

Eosinophilic Asthma Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for eosinophilic asthma. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of eosinophilic asthma drug candidates.

Biological: Benralizumab

Benralizumab is a monoclonal antibody that targets the IL-5 receptor, leading to the rapid depletion of eosinophils, which helps reduce asthma exacerbations. It is being evaluated in the Benralizumab Airway Remodeling Study, sponsored by AstraZeneca, to assess its impact on structural changes and lung function in patients with severe eosinophilic asthma. This Phase IV study will track outcomes over 48 weeks in patients who are unresponsive to standard asthma therapies.

Drug: Dexpramipexole Dihydrochloride

Dexpramipexole, sponsored by Areteia Therapeutics, is currently in Phase III development to assess its efficacy and safety in treating severe eosinophilic asthma. This oral small molecule works by inhibiting eosinophil maturation in the bone marrow, reducing blood eosinophil levels. The study involves approximately 1,395 participants globally, with a 52-week treatment period and completion expected by July 2026.

Reasons To Buy This Report

The Eosinophilic Asthma Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for eosinophilic asthma. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into eosinophilic asthma collaborations, regulatory environments, and potential growth opportunities.

Key Questions Answered in the Eosinophilic Asthma - Pipeline Insight Report

• Which companies/institutions are leading the eosinophilic asthma drug development?
• What is the efficacy and safety profile of eosinophilic asthma pipeline drugs?
• Which company is leading the eosinophilic asthma pipeline development activities?
• What is the current eosinophilic asthma commercial assessment?
• What are the opportunities and challenges present in the eosinophilic asthma drug pipeline landscape?
• What is the efficacy and safety profile of eosinophilic asthma pipeline drugs?
• Which company is conducting major trials for eosinophilic asthma drugs?
• Which companies/institutions are involved in eosinophilic asthma collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in eosinophilic asthma?

This product will be delivered within 3-5 business days.